Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Study Drug Clear all
Active, not recruiting Early Phase 1 Interventional

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

NCT05416333
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
azelaic acid, usual medication for CCCA
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 10, 2026, 5:13 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

NCT03715933
View directory record Official record
Conditions
Ewing Sarcoma, Colorectal Adenocarcinoma
Interventions
INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
12 Years to 85 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

NCT00238433
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

NCT01922752
View directory record Official record
Conditions
Solid Tumors
Interventions
CEP-37440
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

NCT01966419
View directory record Official record
Conditions
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions
ornithine phenylacetate, placebo intravenous infusion
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

NCT02279719
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
BBI608, BBI503, Sorafenib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • Coronado, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

NCT04860830
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Anaheim, California • Culver City, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 10, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

NCT04652700
View directory record Official record
Conditions
HIV Preexposure Prophylaxis
Interventions
ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

NCT03194867
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab SAR650984, Cemiplimab REGN2810
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Denver, Colorado • Kansas City, Kansas • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 10, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 10, 2026, 5:13 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

NCT01479244
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
Biological
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
81
States / cities
Bessemer, Alabama • Mobile, Alabama • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Not applicable Interventional

DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements

NCT00550563
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy
Dietary Supplement · Genetic · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana

NCT01844687
View directory record Official record
Conditions
Smoking, Marijuana
Interventions
CBD
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Lexington, Kentucky • New York, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00182793
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

NCT00808093
View directory record Official record
Conditions
Dyslipidaemias
Interventions
GSK256073
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Not applicable Interventional

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

NCT00000914
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 3 Interventional

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

NCT06584916
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 10, 2026, 5:13 AM EDT
Withdrawn No phase listed Observational

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

NCT01394133
View directory record Official record
Conditions
HIV Infected
Interventions
Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Sep 10, 2026, 5:13 AM EDT
Terminated Not applicable Interventional Results available

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

NCT01974284
View directory record Official record
Conditions
Papillary Thyroid Cancer
Interventions
percutaneous ethanol ablation
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 4 Interventional

A Study of Mouth Rinses in Type 1 and Type 2 Diabetic Participants

NCT04449952
View directory record Official record
Conditions
Gingivits in Diabetics
Interventions
Listerine Cool Mint, 5% Hydroalcohol Mouth Rinse, Colgate Cavity Protection Toothpaste, Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula, Concept Curve Winter Series Toothbrush, Listerine Cool Mint Floss
Other · Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sleep and Breathing in the General Population - Chemical Stimuli

NCT04720547
View directory record Official record
Conditions
Sleep-disordered Breathing
Interventions
Zolpidem, No Treatment
Drug · Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 10, 2026, 5:13 AM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 10, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

NCT01862536
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tadalafil, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
West Los Angeles, California • Denver, Colorado • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 10, 2026, 5:13 AM EDT